
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
ERT announced the establishment of a Phase I QT Center of Excellence, which is an advanced technology that enables pharmaceutical companies, biotechs, and CROs to gain information and data about the cardiac safety profile of their drug candidates at the earliest possible time in the drug development process in order to meet regulatory requirements.
Read the full release






